These findings could be related to the poorer baseline characteristics of the statin nonuser group (e.g., reduced LVEF, high numbers of patients with cardiogenic shock or CPR on admission and high mean level of NT-ProBNP; Table 3 and Table 4) compared with statin users. The gene discussed is NPPB; the disease is Shock.